

Jing Zhang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/688427/publications.pdf>

Version: 2024-02-01

8
papers

1,178
citations

1163117

8
h-index

1588992

8
g-index

8
all docs

8
docs citations

8
times ranked

2947
citing authors

#	ARTICLE	IF	CITATIONS
1	Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening. <i>Cell</i> , 2017, 170, 577-592.e10.	28.9	506
2	TRIM32 Protein Modulates Type I Interferon Induction and Cellular Antiviral Response by Targeting MITA/STING Protein for K63-linked Ubiquitination. <i>Journal of Biological Chemistry</i> , 2012, 287, 28646-28655.	3.4	313
3	VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma. <i>Science</i> , 2018, 361, 290-295.	12.6	134
4	Prolyl hydroxylation by EglN2 destabilizes FOXO3a by blocking its interaction with the USP9x deubiquitinase. <i>Genes and Development</i> , 2014, 28, 1429-1444.	5.9	111
5	EglN2 associates with the NRF1-PGC1 β complex and controls mitochondrial function in breast cancer. <i>EMBO Journal</i> , 2015, 34, 2953-2970.	7.8	58
6	Prolyl hydroxylase substrate adenylosuccinate lyase is an oncogenic driver in triple negative breast cancer. <i>Nature Communications</i> , 2019, 10, 5177.	12.8	27
7	EglN2 contributes to triple negative breast tumorigenesis by functioning as a substrate for the FBW7 tumor suppressor. <i>Oncotarget</i> , 2017, 8, 6787-6795.	1.8	16
8	TET2 Suppresses VHL Deficiency-Driven Clear Cell Renal Cell Carcinoma by Inhibiting HIF Signaling. <i>Cancer Research</i> , 2022, 82, 2097-2109.	0.9	13